SSG
IRWD icon

Summit Securities Group’s Ironwood Pharmaceuticals IRWD Stock Holding History

Summit Securities Group’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-306
Closed -$450 – 1250
2025
Q1 		$450 Buy
+306
New +$729 ﹤0.01% 726

Other funds holding IRWD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Summit Securities Group's IRWD Position: Q2 2025 in Review

Summit Securities Group sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2025, closing a stake of 306 shares — an estimated $450 sold.

Summit Securities Group first reported a position in IRWD in Q1 2025 and held it in 1 quarter. The position peaked at $450 in Q1 2025. 155 funds tracked by Wall St. Rank hold IRWD as of Q2 2025.

  • Summit Securities Group reported no remaining Ironwood Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 306 Ironwood Pharmaceuticals shares in Q2 2025, an estimated $450.
  • Summit Securities Group first reported a position in Ironwood Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Summit Securities Group's Ironwood Pharmaceuticals position peaked at $450 in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.